November 04, 2024
1 min watch
Save
VIDEO: Mycophenolate surfaces as treatment for autoimmune hepatitis
PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine at Stanford University, discusses a plenary session about the “emerging role” of mycophenolate mofetil for the treatment of autoimmune hepatitis.
The data was presented at the ACG Annual Scientific Meeting.
“A role for this ... has to be further defined in our patients whom we manage with autoimmune hepatitis,” Kwo said.
Reference:
- Sawaf B, et al. Comparative Efficacy of Mycophenolate Mofetil vs Azathioprine in Autoimmune Hepatitis: A Systematic Review and Meta-Analysis. Presented at: ACG Annual Scientific Meeting; Oct. 25- 30, 2024; Philadelphia (hybrid meeting).
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Kwo reports serving as an advisor or review panel member for AbbVie; an advisory committee or board member for Aligos, Drug Farm, Gilead and Inventiva; receiving grant or research support from Altimmune, Fractyl, Gilead, Inventiva, Madrigal, Novo Nordisk, Target Registries and Ultragenyx; serving as a consultant for Durect, HepQuant, PPD and Surrozen; and owning stock options in Durect.
Read more about